Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Clin Cancer Res. 2017 Jan 20;23(13):3343–3351. doi: 10.1158/1078-0432.CCR-16-2745

Figure 5. Therapeutic efficacy of VTP, 90Y-DOTA-AR and 90Y-DOTA-AR/VTP combination on PC-3 xenografts.

Figure 5

(A) Individual tumor growth per each cohort is shown. Mice bearing PC-3 xenografts were randomly assigned to 4 different cohorts of sham control (saline and illumination only, n=8), VTP (n=12), 90Y-DOTA-AR (n=12), and combination of 90Y-DOTA-AR and VTP (n=13). 90Y-DOTA-AR alone did not demonstrate statistically significant anti-tumor effect on tumor growth (p = 0.97) while VTP treatment alone had a modest effect on tumor growth compared to control group (p< 0.01). Combination treatment displayed statistically significant antitumor effect compared to 90Y-DOTA-AR alone arm (p < 0.0001) or to VTP alone arm (p < 0.05) suggesting synergy between radiotherapy and VTP. Two-way ANOVA test was utilized for the statistical analysis. (B) The graph shows the median tumor volume as a function of time. This shows a clear demarcation between treatment groups with the combination of 90Y-DOTA-AR plus VTP having a much more pronounced therapeutic effect.